About Holger Wulff, PhD, MBA

My work is characterized by professional experience,
a wealth of methods and foresight

 

Professional Experiance:

  • Substantiated management knowledge from study and practice as reliable basis for resource-oriented, quality-conscious, accurately targeted and therefore successful management of national and international projects
    • Seven years professional consultancy for successful process recording, improvement and automation within interdisciplinary process chains & networks across Europe
    • Overall 16 years of full time professional activity in the pharmaceutical industry
    • Two and a half years experience as consultant for clinical development and marketing
    • Three years in clinical project and line management of a medium-sized CRO located in Berlin – Germany
    • Four years trainer activities in clinical monitoring, relevant regulations and project management as well as for ICH-GCP workshops for personnel in clinical development
    • Seven years experience in clinical Monitoring (CRA, Senior CRA, Lead CRA)

     

    Higher Education:

        • Master of Business Administration (General and finance management)
          Open University of Hagen – Germany / University of Wales – Wales
        • Dissertation (Cancer research / Gene therapy)
          University Medical Center Hamburg-Eppendorf – Germany
        • PhD in Biology (Biochemistry)
          University of Hamburg – Germany and University of Oldenburg – Germany

     

    Languages:

        • German              (native)
        • English               (fluent)

     

    Publications:

      • Dr. Wulff, H. (2011)
        Objectives, concepts, problems and historical origin of the evolutionary management – illustrated through sales policy, Open University of Hagen Germany / University of Wales, Master Thesis (MBA), (22 September 2011)
      • Wulff, H., Krieger, T., Krüger, K., Stahmer, I., Thaiss, F., Schäfer, H., & Block, A (2007)
        Cloning and characterization of an adenoviral vector for highly efficient and Doxycycline suppressible expression of bioactive human single – chain Interleukin 12 in colon cancer, BMC Biotechnology 2007, 7:35 (26 June 2007)
      • Seitz, U., Block, A., Schaefer, A.-C., Wienhold, U., Bohnacker, S.,Siebert, K., Sadikin, J., Seewald, S., Thonke, F., Wulff, H., De Weerth, A., Soehendra, N. (2007)
        Biliary stent clogging solved by Nanotechnology? An in-vitro study of different Anorganic-organic Sol-Gel Coatings for Teflon stants, Gastroenterology 2007, 133:1, (July 2007)